Novavax, Inc. is a clinical stage vaccine company
committed to leading the global fight against infectious diseases by
creating novel, highly potent vaccines that are safer and more
effective than current preventive options.
It's world-class scientific team is using virus-like particle (VLP) technology to tackle influenza viruses – including avian strains that have the potential to cause a pandemic outbreak. Its team has created vaccines designed to protect against various circulating strains of avian influenza as well as seasonal flu. The company have validated their approach in animals and are moving toward clinical testing.
It's world-class scientific team is using virus-like particle (VLP) technology to tackle influenza viruses – including avian strains that have the potential to cause a pandemic outbreak. Its team has created vaccines designed to protect against various circulating strains of avian influenza as well as seasonal flu. The company have validated their approach in animals and are moving toward clinical testing.
Novavax's vision is a holistic approach to controlling the spread of disease. Using a unique portable manufacturing system that allows for rapid mass production, its long-term goal is to be able to rapidly deliver a customized vaccine in the midst of a pandemic.
Novavax plans to apply its particle-based vaccine approach to other viral diseases beyond influenza.